Market Overview

UPDATE: Jefferies Lowers PT on AbbVie on Attractive Entry Point Potential

Share:
Related
Evercore ISI Analyst Breaks Down Amgen's IPR Against AbbVie's Humira Formulation Patent
US Stock Futures Slide Ahead Of GDP Data
Gilead's (GILD) HCV Drug Harvoni Gets Approval in Japan - Analyst Blog (Zacks)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on AbbVie (NYSE: ABBV), but lowered the price target from $54.00 to $51.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

AbbVie closed on Thursday at $43.04.

Latest Ratings for ABBV

DateFirmActionFromTo
Jun 2015Piper JaffrayInitiates Coverage onOverweight
Jun 2015JefferiesMaintainsBuy
May 2015Morgan StanleyAssumesEqual-weight

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABBV)

Around the Web, We're Loving...

Get Benzinga's Newsletters